Qualitative Change in Migraine Prevention?

Roger Cady, Richard B. Lipton

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

A new generation of drugs that target calcitonin gene-related peptide (CGRP) pathways offers a unique opportunity to explore the relationship between responder rates (RRs) and improvement in patient outcomes. The authors hypothesize a "tipping point" exists for patients with a ≥75% migraine response. They propose higher RRs reported in trials with CGRP inhibitory antibodies deliver not only a quantitative change in monthly headache days, but also a qualitative change in function, for a clinically meaningful subpopulation of patients.

Original languageEnglish (US)
JournalHeadache
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Migraine Disorders
Calcitonin Gene-Related Peptide
Headache
Antibodies
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Qualitative Change in Migraine Prevention? / Cady, Roger; Lipton, Richard B.

In: Headache, 01.01.2018.

Research output: Contribution to journalArticle

@article{78834b4ff802474dbff39f686cdc72a3,
title = "Qualitative Change in Migraine Prevention?",
abstract = "A new generation of drugs that target calcitonin gene-related peptide (CGRP) pathways offers a unique opportunity to explore the relationship between responder rates (RRs) and improvement in patient outcomes. The authors hypothesize a {"}tipping point{"} exists for patients with a ≥75{\%} migraine response. They propose higher RRs reported in trials with CGRP inhibitory antibodies deliver not only a quantitative change in monthly headache days, but also a qualitative change in function, for a clinically meaningful subpopulation of patients.",
author = "Roger Cady and Lipton, {Richard B.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1111/head.13354",
language = "English (US)",
journal = "Headache",
issn = "0017-8748",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Qualitative Change in Migraine Prevention?

AU - Cady, Roger

AU - Lipton, Richard B.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - A new generation of drugs that target calcitonin gene-related peptide (CGRP) pathways offers a unique opportunity to explore the relationship between responder rates (RRs) and improvement in patient outcomes. The authors hypothesize a "tipping point" exists for patients with a ≥75% migraine response. They propose higher RRs reported in trials with CGRP inhibitory antibodies deliver not only a quantitative change in monthly headache days, but also a qualitative change in function, for a clinically meaningful subpopulation of patients.

AB - A new generation of drugs that target calcitonin gene-related peptide (CGRP) pathways offers a unique opportunity to explore the relationship between responder rates (RRs) and improvement in patient outcomes. The authors hypothesize a "tipping point" exists for patients with a ≥75% migraine response. They propose higher RRs reported in trials with CGRP inhibitory antibodies deliver not only a quantitative change in monthly headache days, but also a qualitative change in function, for a clinically meaningful subpopulation of patients.

UR - http://www.scopus.com/inward/record.url?scp=85050533966&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050533966&partnerID=8YFLogxK

U2 - 10.1111/head.13354

DO - 10.1111/head.13354

M3 - Article

C2 - 30035299

AN - SCOPUS:85050533966

JO - Headache

JF - Headache

SN - 0017-8748

ER -